Speakers from Touchstone Exploration, Shanta Gold, Savannah Resources and Kavango Resources feature in our Natural Resources webinar on May 25th. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksE-therapeutics Share News (ETX)

Share Price Information for E-therapeutics (ETX)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 29.20
Bid: 27.60
Ask: 29.60
Change: 0.00 (0.00%)
Spread: 2.00 (7.25%)
Open: 29.20
High: 29.50
Low: 28.00
Yest. Close: 29.20
ETX Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

RNS Alerts are a premium feature

Login to your account

myTerminal is a premium feature

Login to your account

Don't have an account? Click here to register.

e-Therapeutics Names New Chief Executive; Plans To Ramp Up Research

Mon, 12th Oct 2020 11:13

(Alliance News) - e-Therapeutics PLC on Monday said Chair Ali Mortazavi will take on the additional role of chief executive officer, as the company ramps up its research & development in the second half of the year.

The Oxford-based drug discovery platform posted a pretax loss in the half ended July 31 of GBP2.7 million, widened from GBP1.5 million a year prior. Administration expenses multiplied to GBP1.5 million from GBP599,000 a year before.

Revenue was at GBP37,000, down from GBP188,000 a year before.

The company had GBP15.1 million in cash at July 31, following a GBP13.2 million fundraise during the first half.

The company expects its spending to increase as it ramps up research and development in the second half following the fundraise. As a result its underlying cash burn will be higher in the second half than in the first.

e-Therapeutics said: "Although we have enhanced the data and software resources of the current platform during the year to date, we will progress further with streamlining and scaling the existing platform capabilities in the second half. We will also make further progression on the expansion into RNAi.

"Whilst we have been planning the best therapeutic areas in which to commence our internal asset discovery programmes, expenditure on these will also continue at a higher level in the second half of the financial year. "

"We remain in active discussions with large pharmaceutical and biotechnology companies and look forward to the future with confidence," the company added.

New CEO Mortazavi, who is the former chief executive of Silence Therapeutics PLC, will retain his position as executive chair, a role he took up in February.

Non-Executive Director Trevor Jones said: "Since his appointment in February, Ali has re-energised the company and, importantly, played a significant role in restructuring the portfolio; including the establishment of a research programme on RNAi...a key area for important new therapies for a number of major diseases. We are delighted that in addition to his role as chairman he has accepted our invitation to lead the team as chief executive officer."

e-Therapeutics shares were down 1.6% at 15.01 pence each in London on Monday morning.

By Greg Roxburgh; gregroxburgh@alliancenews.com

Copyright 2020 Alliance News Limited. All Rights Reserved.

More News

UK earnings, trading statements calendar - next 7 days

UK earnings, trading statements calendar - next 7 days

6 May 21 15:51

AIM WINNERS & LOSERS: Bigblu Broadband rises on Quickline stake sale

AIM WINNERS & LOSERS: Bigblu Broadband rises on Quickline stake sale

23 Apr 21 11:31

e-Therapeutics gets two payments from Galapagos under collaboration

e-Therapeutics gets two payments from Galapagos under collaboration

23 Apr 21 11:29

E-therapeutics to receive two milestone payments from Galapagos

(Sharecast News) - E-therapeutics has met two key milestones in its collaboration with small-molecule medicines specialist Galapagos, it announced on Friday.

23 Apr 21 10:18

EXECUTIVE CHANGES: F&C Investment Trust hires CBI chief economist

EXECUTIVE CHANGES: F&C Investment Trust hires CBI chief economist

29 Mar 21 15:13

EXECUTIVE CHANGES: New CFOs for Sensyne, Focusrite, Bango, 4D Pharma

EXECUTIVE CHANGES: New CFOs for Sensyne, Focusrite, Bango, 4D Pharma

1 Mar 21 16:41

IN BRIEF: e-Therapeutics Says Tests Underway For GalNAc-siRNA Platform

IN BRIEF: e-Therapeutics Says Tests Underway For GalNAc-siRNA Platform

1 Feb 21 12:04

IN BRIEF: e-Therapeutics Reports Results Of Covid-19 Compounds Testing

IN BRIEF: e-Therapeutics Reports Results Of Covid-19 Compounds Testing

8 Dec 20 20:38

e-Therapeutics Names New Chief Executive; Plans To Ramp Up Research

e-Therapeutics Names New Chief Executive; Plans To Ramp Up Research

12 Oct 20 11:13

e-Therapeutics 're-energised' by Mortazavi appointment

(Sharecast News) - Drug discovery and development company e-Therapeutics said on Monday that it was feeling "re-energised" by the addition of former Silence Therapeutics boss Ali Mortazavi amid active discussions with large pharmaceutical and biotechnology firms regarding potential collaborations.

12 Oct 20 10:06

IN BRIEF: e-Therapeutics Bags GBP750,000 From Retail Offer

IN BRIEF: e-Therapeutics Bags GBP750,000 From Retail Offer

8 Jul 20 16:21

UK WINNERS & LOSERS SUMMARY: HSBC Shares Fall Amid Investec Downgrade

UK WINNERS & LOSERS SUMMARY: HSBC Shares Fall Amid Investec Downgrade

8 Jul 20 10:45

IN BRIEF: e-Therapeutics Plans GBP12 Million Fundraise

IN BRIEF: e-Therapeutics Plans GBP12 Million Fundraise

7 Jul 20 19:05

UK TRADING UPDATE SUMMARY: XLMedia To Sell Finnish Casino Assets

UK TRADING UPDATE SUMMARY: XLMedia To Sell Finnish Casino Assets

10 Jun 20 13:15

E-therapeutics enters collaboration deal with Galapagos

(Sharecast News) - E-therapeutics has entered a collaboration agreement with Galapagos to identify new therapeutic approaches to modulate a specific mechanism involved in idiopathic pulmonary fibrosis (IPF), and potentially in other fibrotic indications, it announced on Wednesday.

10 Jun 20 09:20

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.